MDRNA Sells Osteoporosis Drug

Luke Timmerman4/1/09

MDRNA, the Bothell, WA-based developer of drugs using RNA interference technology, said today it has sold its assets related to a nasal spray drug for osteoporosis to Par Pharmaceutical. MDRNA (NASDAQ: MRNA) will receive an undisclosed upfront cash payment, and a double-digit percentage royalty on sales of the product, a generic form of calcitonin-salmon nasal spray. MDRNA has been running low on cash, and it noted that Par will assume manufacturing and operating costs related to the drug.

Luke Timmerman is the National Biotech Editor of Xconomy. E-mail him at ltimmerman@xconomy.com Follow @